Department of Biochemistry, West Virginia University, Morgantown, WV, USA.
WVU Cancer Institute, School of Medicine, West Virginia University, Morgantown, WV, USA.
Oncogene. 2021 Sep;40(37):5651-5664. doi: 10.1038/s41388-021-01969-1. Epub 2021 Jul 29.
Metastatic breast cancer causes most breast cancer-associated deaths, especially in triple negative breast cancers (TNBC). The metastatic drivers of TNBCs are still poorly understood, and effective treatment non-existent. Here we reveal that the presence of Aurora-A Kinase (AURKA) in the nucleus and metastatic dissemination are molecularly connected through HIF1 (Hypoxia-Inducible Factor-1) signaling. Nuclear AURKA activates transcription of "hypoxia-induced genes" under normoxic conditions (pseudohypoxia) and without upregulation of oxygen-sensitive HIF1A subunit. We uncover that AURKA preferentially binds to HIF1B and co-localizes with the HIF complex on DNA. The mass-spectrometry analysis of the AURKA complex further confirmed the presence of CBP and p300 along with other TFIIB/RNApol II components. Importantly, the expression of multiple HIF-dependent genes induced by nuclear AURKA (N-AURKA), including migration/invasion, survival/death, and stemness, promote early cancer dissemination. These results indicate that nuclear, but not cytoplasmic, AURKA is a novel driver of early metastasis. Analysis of clinical tumor specimens revealed a correlation between N-AURKA presence and decreased patient survival. Our results establish a mechanistic link between two critical pathways in cancer metastasis, identifying nuclear AURKA as a crucial upstream regulator of the HIF1 transcription complex and a target for anti-metastatic therapy.
转移性乳腺癌是导致大多数乳腺癌相关死亡的原因,尤其是在三阴性乳腺癌(TNBC)中。TNBC 的转移性驱动因素仍知之甚少,且尚无有效的治疗方法。在这里,我们揭示了核中的 Aurora-A 激酶(AURKA)和转移性扩散通过 HIF1(缺氧诱导因子-1)信号在分子水平上是相关的。在常氧条件下(伪缺氧),核 AURKA 激活“缺氧诱导基因”的转录,而无需氧敏感的 HIF1A 亚基的上调。我们发现 AURKA 优先与 HIF1B 结合,并与 HIF 复合物在 DNA 上共定位。AURKA 复合物的质谱分析进一步证实了 CBP 和 p300 以及其他 TFIIB/RNApol II 成分的存在。重要的是,核 AURKA(N-AURKA)诱导的多个 HIF 依赖性基因的表达,包括迁移/侵袭、存活/死亡和干细胞特性,促进了早期癌症扩散。这些结果表明,核 AURKA 而非细胞质 AURKA 是早期转移的新驱动因素。对临床肿瘤标本的分析表明,N-AURKA 的存在与患者生存时间的缩短之间存在相关性。我们的研究结果在癌症转移的两个关键途径之间建立了一个机制联系,确定核 AURKA 是 HIF1 转录复合物的关键上游调节剂,也是抗转移治疗的靶点。